Alghamdi Mohammed, Bazarbashi Shouki, Mahrous Mervat, Alshaer Omar, Mostafa Gad Ahmed, Aseafan Mohamed, Abdelgelil Mai, Alshabi Redhwan Mohammed, Alghanmi Hosam Ali, Naser Nasser Ahmed, Al Hariri Husam, ALHamad Abdulaziz, Al-Saleh Khalid, Abdel-Aziz Nashwa, Elsamany Sherif
Department of Medical Oncology, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia.
Department of Medical Oncology, Oncology Centre, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
J Oncol. 2022 Sep 12;2022:3796783. doi: 10.1155/2022/3796783. eCollection 2022.
The outcome of patients with refractory metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil (FTD/TPI) beyond the second-line has not been studied in Saudi Arabia. Therefore, this multicenter retrospective analysis was conducted to evaluate the efficacy of FTD/TPI.
This multicenter retrospective analysis included five centers in Saudi Arabia. FTD/TPI was administered to all the patients beyond the oxaliplatin- and irinotecan-based chemotherapy regimens. The electronic medical records were reviewed, and progression-free survival (PFS) and overall survival (OS) were determined.
The study included 100 patients with a mean age of 55.4 ± 11.8 years. The overall response to FTD/TPI was 4%. The median PFS was 4 months (95% confidence interval (CI) 3.487-4.513), and the median OS was 11 months (95% CI, 9.226-12.771). In a Cox regression analysis of the independent predictors for PFS, advanced stage of the disease ( = 0.037; HR, 2.614; and CI, 1.102-7.524), presence of lymph node metastasis ( = 0.018; HR, 3.664; and 95% CI, 1.187-8.650), and >2 metastatic sites ( = 0.020; HR, 1.723; and 95% CI, 1.089-2.727) were independent factors predicting disease progression. The Cox regression analysis confirmed that age ≥ 55 years ( = 0.046; HR, 1.667; and 95%, 1.097-3.100), advanced disease stage ( = 0.044; HR, 1.283; and 95% CI, 1.035-2.940), prior use of adjuvant chemotherapy ( = 0.037; HR, 0.892; and 95% CI, 0.481-0.994), liver metastasis ( = 0.025; HR, 2.015; and 95% CI, 1.091-3.720), >2 metastatic sites ( = 0.038; HR, 1.248; and 95% CI, 1.036-1.846), development of neutropenia after receiving first cycle of FTD/TPI ( = 0.042; HR, 1.505; and 95% CI, 1.064-2.167), and increased number of FTD/TPI cycles ( = 0.002; HR, 0.769; and 95% CI, 0.664-0.891) were independent variables for OS.
Treatment with FTD/TPI is feasible and effective in daily clinical practice in Saudi Arabian patients. The risk of progression increased with advanced disease stage, lymph node metastasis, bone metastasis, and metastasis to >2 sites. Age ≥ 55 years, advanced disease stage, liver metastasis, metastasis to >2 sites, neutropenia after the first cycle of FTD/TPI, and increased number of FTD/TPI cycles were independent factors predicting mortality.
在沙特阿拉伯，尚未对接受三氟尿苷/替匹嘧啶（FTD/TPI）二线以上治疗的难治性转移性结直肠癌（mCRC）患者的治疗结果进行研究。因此，进行了这项多中心回顾性分析，以评估FTD/TPI的疗效。
这项多中心回顾性分析纳入了沙特阿拉伯的五个中心。所有患者在接受基于奥沙利铂和伊立替康的化疗方案后给予FTD/TPI。查阅电子病历，确定无进展生存期（PFS）和总生存期（OS）。
该研究纳入了100例患者，平均年龄为55.4±11.8岁。FTD/TPI的总体缓解率为4%。中位PFS为4个月（95%置信区间（CI）3.487 - 4.513），中位OS为11个月（95%CI，9.226 - 12.771）。在PFS独立预测因素的Cox回归分析中，疾病晚期（P = 0.037；HR，2.614；CI，1.102 - 7.524）、存在淋巴结转移（P = 0.018；HR，3.664；95%CI，1.187 - 8.650）和转移部位>2个（P = 0.020；HR，1.723；95%CI，1.089 - 2.727）是预测疾病进展的独立因素。Cox回归分析证实，年龄≥55岁（P = 0.046；HR，1.667；95%，1.097 - 3.100）、疾病晚期（P = 0.044；HR，1.283；95%CI，1.035 - 2.940）、既往使用辅助化疗（P =
